News
Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of $23.00. Discover outperforming stocks and invest smarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
